Answers are grounded in this paper and cite their sources.
OBJECTIVES: Flow cytometry is essential for the evaluation of lymphoproliferative disorders (LPDs) and their classification. Flow panels routinely incorporate a large array of antibodies, making testing complex and expensive; such panels are likely unnecessary in benign cases or those with straightforward diagnoses. Our aim was to develop a more cost-effective testing strategy based on a retrospective analysis of flow studies for possible LPDs in blood. METHODS: We identified LPD frequencies and types, as well as associated results with patient age and absolute lymphocyte count. RESULTS: We found that the likelihood of LPDs increased with patient age and absolute lymphocyte count and that CD5-positive LPD was the most common LPD diagnosed in our institution (71% of LPDs). Using these data, we devised flow-testing algorithms with a screening test for patients at low risk of disease and a focus on CD5-positive LPD detection, with reflexing as needed. CONCLUSIONS: We project this approach will result in a 40% decrease in antibody utilization.
No takes yet. Share an insight, caveat, or question.
Oberley et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: